Modern chemotherapeutic options for malaria

Lancet Infectious Diseases

Volumn 1, Issue 4, 2001, Pages 242-250

  Winstanley, Peter ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT;

AFRICA; ANIMAL; DEVELOPING COUNTRY; DRUG EFFECT; DRUG RESISTANCE; ECONOMICS; HEALTH CARE POLICY; HUMAN; MALARIA; MORTALITY; PLASMODIUM FALCIPARUM; PUBLIC HEALTH; REVIEW;

AFRICA; ANIMALS; ANTIMALARIALS; DEVELOPING COUNTRIES; DRUG RESISTANCE; HEALTH POLICY; HUMANS; MALARIA; PLASMODIUM FALCIPARUM; PUBLIC HEALTH;

EID: 0035524381     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00119-0     Document Type: Review

References (32)

1. Snow R.W., Craig M.H., Deichmann U., Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ. 77:1999;624-640.
2. Brabin B.J., Hakimi M., Pelletier D. An analysis of anemia and pregnancy-related maternal mortality. J Nutr. 131:(suppl 2):2001;604-614.
3. Sachs J. Helping the world's poorest. The Economist Aug. 14:1999;17-20.
4. Trape J.F., Pison G., Preziosi M.P., et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 321:1998;689-697.
5. Bradley D.J., Bannister B. Guidelines for the prevention of malaria in travellers from the United Kingdom. Commun Dis Public Health. 4:2001;84-101.
6. Meshnick S.R. Artemisinin antimalarials: mechanisms of action and resistance. Med Trop (Mars). 58:(suppl 3):1998;13-17.
7. Korsinczky M., Chen N., Kotecka B., Saul A., Rieckmann K., Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 44:2000;2100-2108.
8. Sabchareon A., Attanath P., Phanuaksook P., et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 92:1998;201-206.
9. Falloon J., Sargent S., Piscitelli S.C., et al. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy. 19:1999;1050-1056.
10. Bakshi R., Hermeling-Fritz I., Gathmann I., Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 94:2000;419-424.
11. O′Neill P.M., Bray P.G., Hawley S.R., Ward S.A., Park B.K. 4-Aminoquinolines - past, present, and future: a chemical perspective. Pharmacol Ther. 77:1998;29-58.
12. Amodiaquine for treating malaria (Cochrane Review). In: Olliaro P., Mussano P., The Cochrane Library, issue 3. Oxford: Update Software, 2001.
13. Wesche D.L., Schuster B.G., Wang W.X., Woosley R.L. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther. 675:2000;521-529.
14. Lightbown I.D., Lambert J.P., Edwards G., Coker S.J. Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. Br J Pharmacol. 132:2001;197-204.
15. Phillips-Howard P.A., ter Kuile F.O. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf. 12:1995;370-383.
16. Nosten F., Vincenti M., Simpson J., et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis. 28:1999;808-815.
17. Supanaranond W., Suputtamongkol Y., Davis T.M., et al. Lack of a significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Trans R Soc Trop Med Hyg. 91:1997;694-706.
18. Ward S.A., Watkins W.M., Mberu E., et al. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol. 27:1989;781-787.
19. Fidock D, Nomura T, Wellems T. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol; 54: 1140-47.
20. WHO. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94: suppl 1.
21. McGready R., Brockman A., Cho T., et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 94:2000;689-693.
22. Bloland P.B., Lackritz E.M., Kazembe P.N., Were J.B., Steketee R., Campbell C.C. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis. 167:1993;932-937.
23. White N.J., Nosten F., Looareesuwan S., et al. Averting a malaria disaster. Lancet. 353:1999;1965-1967.
24. van Hensbroek M.B., Morris-Jones S., Meisner S., et al. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg. 89:1995;672-676.
25. Mutabingwa T, Nzila A, Mberu E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet (in press).
26. Nzila A., Nduati E., Mberu E., et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long acting antifolate pyrimethamine/sulfadoxine compared with the shorter acting chlorproguanil-dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 181:2000;2023-2028.
27. Bloland P.B., Ettling M., Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ. 78:2000;1378-1388.
28. The Novartis Foundation for Sustainable Development (NFSD) http://www.foundation.novartis.com/malaria_riamet_china.htm , accessed 2nd Oct 2001.
29. Sachs J.D. A new global commitment to disease control in Africa. Nat Med. 7:2001;521-523.
30. Shretta R., Walt G., Brugha R., Snow R. A political analysis of corporate drug donations: the example of Malarone in Kenya. Health Policy Plan. 16:2001;161-170.
31. Artemisinin derivatives for treating severe malaria (Cochrane Review). In: McIntosh HM, Olliaro P. The Cochrane Library, issue 3. Oxford: Update Software, 2001.
32. Foster S. Treatment of malaria outside the formal health services. J Trop Med Hyg. 98:1995;29-34.